Laboratory biomarkers and frailty: Presentation of the FRAILOMIC initiative

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 10, 2015, Pages e253-e255

  Lippi, Giuseppe ^a   Jansen Duerr, Pidder ^b   Viña, Jose ^c   Durrance Bagale, Anna ^d   Abugessaisa, Imad ^e   Gomez Cabrero, David ^e   Tegnér, Jesper ^e   Grillari, Johannes ^f,g   Erusalimsky, Jorge ^h   Sinclair, Alan ⁱ   Rodriguez Manãs, Leocadio ^j  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Niche Science and Technology   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Evercyte   (Austria)

^g UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^h CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

ⁱ LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^j HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ALPHA ACTININ 3; ANGIOTENSINOGEN; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL; GALECTIN 3; GELATINASE B; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MITOCHONDRIAL DNA; MYELOPEROXIDASE; MYOSTATIN; NITRIC OXIDE SYNTHASE; PRASTERONE; PROCALCITONIN; SELECTIN; STROMELYSIN 3; SUPEROXIDE DISMUTASE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR; VASCULOTROPIN; VITAMIN D RECEPTOR;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE SEVERITY; EUROPE; EXERCISE TOLERANCE; FRAILTY; HUMAN; LETTER; MANAGED CARE; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; PREVALENCE; PRIORITY JOURNAL; AGED; FRAIL ELDERLY; GERIATRIC ASSESSMENT; PROCEDURES;

AGED; BIOMARKERS; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS;

EID: 84941195646     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0147     Document Type: Letter

References (10)

1. Rodríguez-Mañas L, Sinclair AJ. Frailty: the quest for new domains, clinical definitions and subtypes. Is this justified on new evidence emerging? J Nutr Health Aging 2014;18:92-4.
2. Rodríguez-Artalejo F, Rodríguez-Mañas L. The frailty syndrome in the public health agenda. J Epidemiol Community Health 2014;68:703-4.
3. Laosa O, Alonso C, Castro M, Rodriguez-Manas L. Pharmaceutical interventions for frailty and sarcopenia. Curr Pharm Des 2014;20:3068-82.
4. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381:752-62.
5. Lippi G, Plebani M. Biomarker research and leading causes of death worldwide: a rather feeble relationship. Clin Chem Lab Med 2013;51:1691-3.
6. Plebani M. From symptoms to biomarkers: a change of paradigm. Clin Chem Lab Med 2014;52:1513-5.
7. Lippi G, Sanchis-Gomar F, Montagnana M. Biological markers in older people at risk of mobility limitations. Curr Pharm Des 2014;20:3222-44.
8. Fernández-Garrido J, Ruiz-Ros V, Buigues C, Navarro-Martinez R, Cauli O. Clinical features of prefrail older individuals and emerging peripheral biomarkers: a systematic review. Arch Gerontol Geriatr 2014;59:7-17.
9. Plebani M. Harmonization in laboratory medicine: the complete picture. Clin Chem Lab Med 2013;51:741-51.
10. Hens K, Berth M, Armbruster D, Westgard S. Sigma metrics used to assess analytical quality of clinical chemistry assays: importance of the allowable total error (TEa) target. Clin Chem Lab Med 2014;52:973-80.